

# The impact of depression on diabetes

## An inextricable relationship

**KAY WILHELM** AM, MB BS, MD, FRANZCP

**WEI-MAY SU** BSc(Med), MB BS, MMH(GP), FRACGP

*Depression and diabetes are two of the most common chronic illnesses in general practice. Sensitive and holistic management of these conditions as coinciding comorbidities requires an understanding of their multifaceted, bidirectional relationship. Regular screening and monitoring for both conditions are recommended.*

### Key points

- **Depression and diabetes have a bidirectional relationship, precipitated by common environmental and psychosocial factors and shared physiological mechanisms, including dysregulation of the hypothalamic–pituitary–adrenal axis.**
- **Screening and regular review over multiple visits are essential for people with either condition, and should include a comprehensive annual review in patients with an existing diagnosis of diabetes.**
- **Precise questioning in taking a history offers opportunities for targeted treatment strategies.**
- **Management of coinciding depression and diabetes requires a supportive, sensitive and holistic approach, with the aims of simplifying pharmacotherapy and reducing anxiety and distress where possible. Psychotherapy should be considered.**
- **Improving health outcomes for people with one condition increases the likelihood of reaching treatment targets in the other.**




**D**epression and diabetes are common conditions that are frequently comorbid, and each impacts on the other. Compared with people without diabetes, depression prevalence rates can be as much as three times higher in people with type 1 diabetes and twice as high in people with type 2 diabetes.<sup>1,2</sup> Prevalence rates vary widely because of the range of methods for defining depression. Sadly, diabetes prevalence has been increasing yearly in Australia.<sup>3</sup>

A paper entitled ‘Depression and diabetes: a potentially lethal combination’ gave a sobering assessment of the relationship: ‘Depression has been linked to having a higher number of Framingham risk factors (i.e. smoking, obesity, sedentary lifestyle) for cardiac disease in patients with diabetes and ... poor adherence to self-care regimens, such as glucose monitoring, diet, exercise regimens, taking medications as prescribed. Depression is also associated with physiologic dysregulation of the hypothalamic–pituitary–adrenal (HPA) axis and sympathetic nervous system, as well as an increase in inflammatory markers, which may also adversely affect the course of diabetes. Given the adverse effect on self-care and physiological dysregulation, it is not surprising that longitudinal studies have also shown that depression is linked with an increased risk of microvascular and macrovascular complications ... Comorbid depression is not only linked to a higher risk for diabetic complications, but also a higher risk for mortality.’<sup>4</sup>

ENDOCRINOLOGY TODAY 2024; 13(3): 19-27

First Published *MedicineToday* 2023; 24(1-2): 30-38

Professor Wilhelm is a Liaison Psychiatrist at St Vincent’s Hospital; Professor at the School of Medicine, University of Notre Dame; and Conjoint Professor in the School of Psychiatry, UNSW, Sydney. Dr Su is a General Practitioner in Sydney; Academic Lead (GP) at HETI, Higher Education, Master of Psychiatric Medicine Program; and Adjunct Clinical Senior Lecturer at the School of Medicine, University of Notre Dame, Sydney, NSW.



**Figure 1. Physiological association between type 2 diabetes and depression.**

Abbreviations: ACTH = adrenocorticotropic hormone; AGEs = advanced glycation end products; CRH = corticotrophin-releasing hormone; SNS = sympathetic nervous system.

Reproduced and adapted under a Creative Commons Attribution 4.0 International license from: Habib S, Sangaraju SL, Yezep D, Grandes XA, Talanki Manjunatha R. The Nexus between diabetes and depression: a narrative review. *Cureus* 2022;14: e25611.

Depression can be seen as an understandable reaction to the demands of diabetes as a lifelong condition with possible significant, often debilitating complications. Some other potential mechanisms that may underlie the high coprevalence include lifestyle factors, genetics and family history, metabolic processes, temperament and coping styles. There is also evidence suggesting that familial relationships and burden of a lifelong disorder with onset early in personality development may contribute to increased vulnerability to depression.<sup>1,2</sup>

This article discusses the depression–diabetes relationship and the management

of depression in those with diabetes, and then considers how GPs can screen for and assess depression in people with diabetes and problem solve medication issues.

### Physiological factors

There are bidirectional effects of stress and labile blood sugars. HPA axis disruption in depression can manifest as sub-clinical hypercortisolism, blunted diurnal cortisol rhythm or hypocortisolism with impaired glucocorticoid sensitivity and increased inflammation.<sup>5,6</sup> Diabetes has similar effects on the HPA axis, and is accentuated by chronic stress (Figure 1).

Cognition and mood are affected by

hyperglycaemia and, potentially, hypoglycaemia. Brain MRIs of people with type 1 diabetes have shown higher pre-frontal glutamate-glutamine-gamma-aminobutyric acid (GABA) levels than in healthy controls, which correlate with mild depressive symptoms.<sup>6</sup> The anti-inflammatory effect of GABA may be crucial in the pancreatic islets as GABA has a role in increasing the survival of insulin-secreting beta cells. When beta cells decrease in number and disappear from the islets, GABA is also decreased, along with its protective shielding of the beta cells. Increases in inflammatory molecules may weaken and even kill the remaining beta cells.<sup>7</sup> Further, animal models have shown that diabetes negatively affects hippocampal integrity and neurogenesis, which may interact with other aspects of neuroplasticity and contribute to mood symptoms in diabetes.<sup>8</sup>

### Linked pathogenesis

There is growing interest in the proposition that depression and type 2 diabetes have shared origins involving a cytokine-mediated inflammatory response dysregulation of the HPA axis.<sup>1,2</sup> Throughout life, these pathways can lead to insulin resistance, cardiovascular disease, depression, increased risk of type 2 diabetes and increased mortality – although mechanisms are not as clear for type 1 diabetes.

Later-onset cerebral microvascular disease can lead to ‘vascular depression’, often with melancholic symptoms. Longer-term noncardiovascular complications of diabetes also arise at this stage of life, including cancer, liver disease and cognitive dysfunction; these are also often comorbid with depression.<sup>1</sup>

### Environmental and social factors

Factors such as socioeconomic status and local environment influence predisposition to depression and diabetes (Figure 2). Poor physical environments (e.g. traffic, noise, decreased walkability, lack of green space) and social environments (e.g. lower social cohesion and social capital, increased violence, decreased residential stability) are


associated with poorer diet and physical activity patterns, obesity, diabetes, hypertension and depression.<sup>1,9,10</sup> Adverse neighbourhood environments have also been associated with HPA axis dysfunction, a blunted circadian rhythm and enhanced inflammation.<sup>1</sup> Of note, smoking and depression are bidirectionally associated and both increase insulin resistance.

### Treatment-related factors and complications

Apart from psychological factors, the psychosocial burden of a diabetes diagnosis and its potential complications predispose people living with diabetes to depressive symptoms. Table 1 provides some questions that clinicians can ask to assess for depression in people living with diabetes. Patients with depression can neglect their self-care and, importantly, their diabetes management. A meta-analysis of 47 independent study samples, including 17,319 participants, found that depression was significantly associated with missed medical appointments and neglecting recommendations about diet, exercise, medication use, blood glucose monitoring and foot care.<sup>11</sup> The GP's role in providing recommended diabetes care is discussed in the Box.

Antidepressant medications can contribute to the risk of diabetes. Randomised controlled trials have shown that these medications vary in their effects on appetite, weight and blood glucose levels (both hyperglycaemic and hypoglycaemic effects have been observed).<sup>12</sup> Selective serotonin reuptake inhibitors (SSRIs) effectively treat depression in people living with diabetes and positively influence glycaemic control. (See also the section 'Antidepressants and diabetes' later in this article.)

A one-point increase in scores for depressive symptoms was found to result in a 10% increased risk of nonadherence to fruit and vegetable intake and foot care in people with diabetes.<sup>1</sup> This suggests a mutually reinforcing phenomenon, where poorer adherence to self-care may increase blood glucose levels, contributing to depressive symptoms and a decline in self-care behaviours.



**Figure 2. Pathophysiological factors in diabetes and depression.**

Abbreviations: ANS = autonomic nervous system; HPA = hypothalamic-pituitary-adrenal.

Reproduced and adapted under a Creative Commons Attribution 4.0 International license from: Habib S, Sangaraju SL, Yopez D, Grandes XA, Talanki Manjunatha R. The Nexus between diabetes and depression: a narrative review. *Cureus* 2022; 14: e25611.

<b>Table 1. Questions to help assess depression in people with diabetes</b>	
<b>Assessment</b>	<b>Examples of questions for the patient</b>
Is there a depressive episode?	<p>Two simple opening questions:</p> <ul style="list-style-type: none"> <li>• During the past month, have you been bothered by having little interest or pleasure in doing things?</li> <li>• During the past month, have you been bothered by feeling down, depressed or hopeless?</li> </ul> <p>Alternative questions:</p> <ul style="list-style-type: none"> <li>• How are you sleeping? How is your appetite? How are your energy levels?</li> <li>• Are you depressed? Have you lost interest in things?</li> <li>• Determine if the person is being more self-critical or tougher on themselves. This can be followed by other questions related to depression (loss of motivation, concentration, guilt, suicidal ideation) or refer to self-report measure</li> <li>• How are you managing currently? Have you had any changes in your condition?</li> </ul>
Relationship with diabetes?	<ul style="list-style-type: none"> <li>• How is your diabetes now?</li> <li>• Have you had any changes in your condition?</li> <li>• How are you managing?</li> <li>• How have any changes in your condition or issues with management impacted on your self-care for diabetes?</li> </ul>

Diabetes can present with or exacerbate fatigue and ‘brain fog’, which can impact motivation and activity levels. People living with diabetes and clinicians can misinterpret these symptoms as psychological in cause, particularly in those with prior history of depression.<sup>1,5,13</sup>

**Recommended general practice care for people with diabetes**

The burden of a diabetes diagnosis can predispose people living with the condition to depressive symptoms. Ensuring the best possible management of diabetes can reduce these symptoms. The annual review of diabetes care by GPs is an important part of this, and timing should be tailored to each individual patient. The objectives outlined below may be addressed over multiple visits.

A GP’s annual review of diabetes care includes:

- implementing preventive care
- screening for complications of diabetes


The review should also consider:

- referral for pathology (HbA1c, UEC/LFT, urine microalbumin)
- cardiovascular screening (lipids, blood pressure, BMI)
- diabetic foot review
- eye checks
- asking about physical activity, diet, smoking, alcohol, use of other recreational substances and general mental wellbeing
- possible referral to a specialist, e.g. optometrist or ophthalmologist, dentist, podiatrist, endocrinologist, cardiologist, nephrologist or diabetes educator
- ensuring vaccinations are up to date
- checking that other age or culturally appropriate preventive screening is performed (<https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/preventive-activities-in-general-practice/about-the-red-book>)
- regular screening for depression

Abbreviations: BMI = body mass index; HbA1c = glycated haemoglobin; LFT = liver function tests; UEC = urea, electrolytes, creatinine.

**Table 2. Focused history-taking on depression and diabetes**

Assessment	Examples of questions for the patient
Lifetime history of depression	<ul style="list-style-type: none"> <li>• When was your first episode? Any other episodes since?</li> <li>• When was the worst time? What helped? How were you between episodes? Were they similar?</li> </ul>
Determine predisposing factors and their precipitants	<p><b>Determine any recent stressors the person may have experienced and the impact these had on daily life:</b></p> <ul style="list-style-type: none"> <li>• Have there been changes in your life? Any other health issues?</li> <li>• Any recent stressors? What is the impact on daily life?</li> <li>• What strengths have you applied in past life crises?</li> </ul>
<p>Assess for evidence of melancholic depression, bipolar disorder, psychotic depression, personality disorder, anxiety disorders</p> <p>Screens for depression and anxiety are available<sup>12</sup> (see <a href="https://www.apa.org/depression-guideline/patient-health-questionnaire.pdf">https://www.apa.org/depression-guideline/patient-health-questionnaire.pdf</a> and <a href="https://adaa.org/sites/default/files/GAD-7_Anxiety-updated_0.pdf">https://adaa.org/sites/default/files/GAD-7_Anxiety-updated_0.pdf</a>)</p>	<p><b>Changes in mood and habits:</b></p> <ul style="list-style-type: none"> <li>• How are you spending your day and is this different from normal? Are you able to look forward to things you normally enjoy, such as ...? Can you be cheered up and if so, what lifts your mood? Do you enjoy activities as much as usual when you get started?</li> </ul> <p><b>Changes in sleeping habits:</b></p> <ul style="list-style-type: none"> <li>• How are you sleeping? What time are you waking up and is it your normal time? Is there a change in your mood and energy over the day and is there a specific pattern?</li> </ul> <p><b>Motivation:</b></p> <ul style="list-style-type: none"> <li>• Have you found it difficult to get going, especially in the mornings/had difficulty getting out of bed/showering? Have you felt apathetic/empty inside?</li> </ul> <p><b>Suicidal ideation:</b></p> <ul style="list-style-type: none"> <li>• Have you thought that life was hopeless/not worth living/had any plans to hurt yourself?</li> </ul> <p><b>History of depression:</b></p> <ul style="list-style-type: none"> <li>• Do you have a family history of depression or bipolar disorder? Have you ever had any mood swings where you are more energetic or ‘wired’? Has anyone ever said you were manic?</li> </ul> <p><b>Worries or anxiety:</b></p> <ul style="list-style-type: none"> <li>• Are you preoccupied with any thoughts or ideas? Have you had any worries that seem to be getting you down/things you would not normally worry about/been stewing over things? If no specific worries are stated, ask whether there have been concerns about having a fatal illness, feeling guilty, thinking they are destitute and panic attacks</li> </ul>
<p>Person’s experience of diabetes</p> <p>Screening for depression/diabetes-related distress<sup>15,16</sup></p> <p>Problem Areas in Diabetes scale [PAID] available<sup>16</sup></p>	<ul style="list-style-type: none"> <li>• How old were you when you found out you had diabetes and how were you told? Did you know anyone with diabetes (family, friends, work associates)?</li> <li>• What has having diabetes been like for you? Have you had any problems with self-management (needles, blood, testing regimen)/services?</li> </ul>
<p>Other complicating factors</p> <p>Consider referral to a diabetes educator</p>	<ul style="list-style-type: none"> <li>• Have you had any problems with eating (weight, appetite, bingeing, dieting/self-harm behaviours)?</li> <li>• Have you had any hypoglycaemic episodes?<sup>17</sup> Are there any new issues? Has anything changed recently?</li> </ul>



## Mitigation and management

It has been suggested that people with chronic conditions such as diabetes can feel blame and shame if complications arise. Thus, complications can be reframed more positively by using words focusing on care, so that people are more engaged with their own management and feel more supported.<sup>11</sup> This promotes their working with their healthcare professionals to minimise the risk of complications and to treat early and effectively those that do occur. Resources to aid in this approach are discussed later in this article. Table 2 provides suggestions for focused history-taking in patients with depression and

diabetes.<sup>14-17</sup> When diabetes and depression coexist, treating the underlying diabetes can significantly improve psychosocial functioning and mood. Metformin may assist with weight loss, which may lessen associated shame and guilt. Improving diabetes control can improve peripheral neuropathy, which may have impaired mobility.<sup>18</sup> Patients may need support with core strengthening and gradually increasing their exercise tolerance if there has been significant muscle wasting from prolonged immobility.<sup>19</sup>

Regular blood glucose self-monitoring is important to recognise symptoms and triggers of hypoglycaemia and

hyperglycaemia and their correct interpretation.<sup>1,13</sup> Misconceptions can otherwise make it challenging to maintain blood glucose levels to target, and can be associated with inappropriate compensatory mechanisms.

Anxiety can potentiate medication side effects and nocebo effects, where the person may experience a detrimental effect from treatment triggered by the anticipation that this will occur. Certain medications and insulin require more regular monitoring, which can exacerbate distress. Many people with diabetes report avoiding testing and treatment as it reminds them of the disease process.

<b>Assessment</b>	<b>Questions for the patient</b>
Evidence of cognitive change, cerebrovascular disease	Has there been a change in memory, concentration, memory, concentration or processing? Have you experienced any 'funny turns' or had any previous episodes? Has anyone else been concerned?
History of nicotine, alcohol or other substance use	Do you smoke tobacco/drink alcohol? Are you using any other substances to alter your mood (prescribed or not)?
Medication changes leading to medication interactions or side effects	Have you had medication changes leading to drug interactions, side effects? Have you started any new medications (including complementary and alternative medicines)?
Factors likely to slow or impede recovery	Have you any problems with family/work/personal finance/social network? Is anything else bothering you?
Factors likely to improve recovery	What has helped in your recovery from previous episodes?
<b>How to help</b>	<b>Resources and treatments</b>
Manage comorbid anxiety	This Way Up has cognitive behavioural therapy programs for depression, panic and health anxiety ( <a href="https://thiswayup.org.au/programs/depression-program/">https://thiswayup.org.au/programs/depression-program/</a> ). Diabetes-specific additions may be needed in some cases <sup>24</sup>
Offer support for the perceived burden of diabetes	Cognitive behavioural therapy, interpersonal therapy and acceptance and commitment therapy may be useful <sup>24-26</sup>
Address interpersonal issues	The article: 'Interpersonal therapy in the general practice setting' ( <i>Medicine Today</i> 2017; 18(8): 41-49) presents the case of a person living with diabetes and how interpersonal therapy can be used <sup>25</sup>

<b>Assessment</b>	<b>Medications and treatments</b>
Melancholic features, including loss of interest, guilty ruminations (such as suicidal thoughts and delusions), diurnal mood variation, early morning wakening, psychomotor slowing and/or agitation, cognitive slowing	<ul style="list-style-type: none"> <li>• SNRIs (particularly venlafaxine) and TCAs (amitriptyline and nortriptyline) can be useful. All can affect blood glucose stability</li> <li>• With these antidepressants, start low and increase the dose slowly to avoid side effects, which can be more prominent in older people, those acutely unwell and those with genetic polymorphisms. These antidepressant medications can also reduce neuropathic pain</li> <li>• Nortriptyline is the best tolerated TCA and is also helpful for treatment of migraine and smoking cessation. Again, start at a low dose (e.g. 10 mg daily), and perform regular ECGs for any conduction defects<sup>14</sup></li> </ul>
Fatigue	<ul style="list-style-type: none"> <li>• Consider using a more stimulating antidepressant (e.g. reboxetine, an SSRI or moclobemide)</li> </ul>
Anxiety	<ul style="list-style-type: none"> <li>• Consider using a more sedating antidepressant (SSRIs can cause agitation and should be started at a low dose and titrated up slowly)</li> </ul>
Nausea	<ul style="list-style-type: none"> <li>• SSRIs can cause nausea; start at a low dose and titrate up slowly (e.g. start with one-quarter tablet and increase to half a tablet)</li> </ul>
Significant pain	<ul style="list-style-type: none"> <li>• Start with cognitive behavioural therapy, mindfulness, physical measures (e.g. myofascial releases, stretching to address muscular spasm, and ensuring low tone and core muscle weakness is addressed). Bed rest will prolong pain so encourage gentle movement even if only static movement is possible. Some antidepressants are helpful for neuropathic pain (see above)</li> </ul>
Problems with sleep	<ul style="list-style-type: none"> <li>• Mirtazapine can be useful, and can also help pain</li> </ul>
Abbreviations: SNRI = serotonin and noradrenaline reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor; TCA = tricyclic antidepressant.	

**Table 5. Resources for GPs on depression and diabetes**

Resources	What is addressed	Strategies	Professional assistance
<b>Diabetes Australia/NDSS</b> ( <a href="https://www.ndss.com.au">https://www.ndss.com.au</a> ) <b>Sydney University Glycaemic Index</b> ( <a href="https://glycemicindex.com/">https://glycemicindex.com/</a> ) <b>Baker Heart and Diabetes Institute</b> ( <a href="https://baker.edu.au/">https://baker.edu.au/</a> )	Acceptance and learning to live with diabetes	<ul style="list-style-type: none"> <li>• Interpersonal therapy for depression, learning to live with diabetes</li> <li>• Acceptance and commitment therapy for acceptance, learning to live with diabetes</li> </ul>	<ul style="list-style-type: none"> <li>• Psychologist</li> </ul>
	Dietary change	<ul style="list-style-type: none"> <li>• Motivational interviewing for behaviour change</li> <li>• Acceptance and commitment therapy for acceptance and learning to live with diabetes</li> </ul>	<ul style="list-style-type: none"> <li>• Dietitian</li> </ul>
	Increasing activity	<ul style="list-style-type: none"> <li>• Motivational interviewing for behaviour change</li> <li>• Acceptance and commitment therapy for acceptance, learning to live with diabetes</li> <li>• Addressing immobility from dependent oedema can also improve mobility</li> <li>• Improving diabetes control may assist with peripheral neuropathy and immobility</li> <li>• Prolonged mobility, poor tone and core muscle weakness may require a rehabilitative approach</li> </ul>	<ul style="list-style-type: none"> <li>• Exercise physiologist</li> <li>• Podiatrist if foot issues</li> </ul>
<b>17 motivational interviewing questions and skills</b> ( <a href="https://positivepsychology.com/motivational-interviewing/">https://positivepsychology.com/motivational-interviewing/</a> ) <b>Australian Government Department of Health and Aged Care Drug Help campaign</b> ( <a href="https://www.health.gov.au/our-work/drug-help">https://www.health.gov.au/our-work/drug-help</a> ) <b>National Alcohol and Other Drug Hotline: 1800 250 015</b> <ul style="list-style-type: none"> <li>• Each state and territory has drug and alcohol resources</li> </ul>	Alcohol, smoking or substance use	<ul style="list-style-type: none"> <li>• Motivational interviewing for behaviour change</li> <li>• Psychotherapy</li> </ul>	<ul style="list-style-type: none"> <li>• Drug and Alcohol services, SMART groups (<a href="https://smartrecoveryaustralia.com.au/">https://smartrecoveryaustralia.com.au/</a>), medication</li> </ul>
People with diabetes registered on the NDSS are eligible for a free glucometer and subsidised continuous glucose monitoring	Regular HbA <sub>1c</sub> screening	<ul style="list-style-type: none"> <li>• Psychoeducation (recognising symptoms of hypoglycaemia and hyperglycaemia, complications of poorly managed diabetes)</li> <li>• Cognitive behavioural therapy for anxiety, needle phobia, mild to moderate depression; often needs to be supplemented with diabetes-specific interventions</li> </ul>	<ul style="list-style-type: none"> <li>• Diabetes educator</li> </ul>

Abbreviations: HbA<sub>1c</sub> = glycated haemoglobin; NDSS = National Diabetes Services Scheme.

Simplifying testing and treatment processes can be helpful. One strategy is to spread blood glucose self-monitoring throughout the week, rather than intensively throughout the day, to ensure the capacity to capture some recordings at a frequency that is tolerable for the individual. Fixed-dose medication combinations may

be suitable for some people with diabetes, and can be available as weekly injections, although some individuals may still prefer daily dosing. Having visual or alarm reminders can also help with medication adherence. Healthcare professionals and the patient working together with regular review can reduce anxiety and the nocebo

effect, particularly on commencing treatment or if the person is experiencing cognitive slowing due to depression.

### Issues related to personality and coping styles

A review of 11 studies found no difference in depression rates among those with

**Table 5. Resources for GPs on depression and diabetes continued**

Resources	What is addressed	Strategies	Professional assistance
<p><b>Diabetes Australia's Preventing complications</b> (<a href="https://www.diabetesaustralia.com.au/living-with-diabetes/preventing-complications/">https://www.diabetesaustralia.com.au/living-with-diabetes/preventing-complications/</a>)</p> <p><b>RACGP and Diabetes Australia's Management of type 2 diabetes: a handbook for general practice</b><sup>27</sup></p>	Engaging with professional review	<ul style="list-style-type: none"> <li>Reduce the risk of developing cardiovascular disease, eye, kidney disease, peripheral neuropathy, dental issues, etc</li> </ul>	<ul style="list-style-type: none"> <li>Endocrinologists, to support the important role GPs play in regularly reviewing diabetes care</li> </ul>
Diabetes Australia/NDSS	Medication and insulin compliance	<ul style="list-style-type: none"> <li>Motivational interviewing for behaviour change</li> <li>Acceptance and commitment therapy for acceptance, learning to live with diabetes</li> <li>Psychoeducation, including importance of recognising symptoms of hypoglycaemia and hyperglycaemia, and complications of poorly managed diabetes</li> <li>Cognitive behavioural therapy for anxiety, needle phobia, mild/moderate depression but often needs to be supplemented with diabetes-specific interventions</li> </ul>	<ul style="list-style-type: none"> <li>Psychologist or psychiatrist to manage concurrent mental health issues, related to need and complexity</li> </ul>
Boyce P, Ma C. Choosing an antidepressant. <i>Aust Prescr</i> 2021; 44: 12-15 <sup>28</sup>	Prescribing antidepressant medications	<ul style="list-style-type: none"> <li>Antidepressant use is associated with elevated CRP levels and incident type 2 diabetes. The risks of taking antidepressants need to be weighed against the risks of depression</li> <li>If melancholic features are present, antidepressants are more likely to be indicated<sup>25</sup></li> </ul>	<ul style="list-style-type: none"> <li>Psychiatrist or psychologist, depending on presentation and need</li> <li>A guide for referral processes for people with diabetes and depression is provided in Chapter 9 in Hendrieckx et al. <i>Diabetes and Emotional Health. A Practical Guide for Health Professionals Supporting Adults with Type 1 or Type 2 Diabetes</i><sup>17</sup></li> </ul>

Abbreviations: CRP = C-reactive protein; HbA<sub>1c</sub> = glycated haemoglobin; NDSS = National Diabetes Services Scheme; RACGP = Royal Australian College of General Practitioners.

undiagnosed diabetes, those with impaired glucose metabolism and people with normal glucose metabolism, suggesting that the actual knowledge of having diabetes and the implications added to the burden and depression onset.<sup>20</sup> The review highlights the importance of how clinicians provide information about diabetes, and what support is given at and after diagnosis. However, no distinction was made for diabetes distress, which can overlap with depression.

Diabetes distress refers to the frequently hidden emotional burdens, stresses and worries that are part of managing a demanding, progressive,

chronic condition like diabetes.<sup>21</sup> Diabetes distress can have early onset in people with diabetes who have experience of diabetes in friends or family.<sup>1,21</sup> Grieving the loss of 'wellness' and what a diagnosis may entail can engender distress even in those who do not fully fit the criteria of major depressive disorder.<sup>21</sup>

There are interesting correlations between adult attachment style and diabetes outcomes, specifically glycated haemoglobin (HbA<sub>1c</sub>) levels and self-management. Ciechanowski et al. found that people with diabetes fit into one of four attachment style groups: secure attachment (about 44%), dismissing attachment (about 36%), fearful

attachment (about 12%) and preoccupied attachment (about 8%).<sup>22,23</sup> Those in the secure group had the lowest mean HbA<sub>1c</sub> level, whereas those in the fearful and preoccupied groups had intermediate HbA<sub>1c</sub> levels. Those with a dismissing attachment style had significantly higher HbA<sub>1c</sub> levels than the other groups and the poorest self-management of their diabetes.

**Management of depression and the effect on glycaemic control**

Individuals may prefer or be more suitable for either psychotherapy (individual, group or online) or pharmacotherapy or a combination of both. As already

discussed in this article, improvement of glycaemic control may bidirectionally improve mood.

A systematic review by van der Feltz suggests that in people with diabetes and subthreshold depression, more individualised psychotherapy may achieve better outcomes – although the mechanisms for this requires more research.<sup>12</sup> Assessment based on the individual's circumstances and needs will still be required. An approach to treating subthreshold depression and comorbid depressive disorder in diabetes is presented in the Flowchart.<sup>12</sup>

### Antidepressants and diabetes

Antidepressant medications (SSRIs, tricyclic antidepressants and serotonin–noradrenaline reuptake inhibitors) are associated with increased risk of diabetes onset, especially with TCAs and concurrent use of SSRIs and TCAs. Antidepressant medications within the same class may differ in terms of their impact on glucose metabolism and should be examined individually. A study that estimated the impact of citalopram, amitriptyline, venlafaxine and escitalopram on glycaemic control in Canadian primary care patients with diabetes found escitalopram to have the least effect.<sup>14</sup>

### Implications for clinical practice

Screening for and addressing depression in people with diabetes is now recognised in the guidelines of several countries and by the International Diabetes Federation, but if GPs are to screen, they need to have interventions that they can provide. Screening can be completed in waiting rooms, as 'homework' or with the assistance of a practice nurse.

For people with diabetes who are depressed, it is helpful to focus on practical strategies, including the specific 'lifestyle factors' of dietary modification and exercise. One of the challenges in diabetes care is the amount of misinformation on diet, so it is best to check the person's information sources.

Tables 1 to 4 provide a framework for assessing depression and its management

in people living with diabetes.<sup>14–17,24–26</sup>

People with comorbid depression and diabetes may require greater support and scaffolding, including naming what they are having difficulty with, particularly in the presence of cognitive slowing and complexity. The simplest way of screening – 'just asking' – is probably the first step (Table 1), followed by more focused history-taking (Tables 2 to 4), although it is not expected that all the questions would be required or attempted at one sitting.

Table 5 outlines useful resources to address a range of complications in people with diabetes and depression, as well as relevant professional who can assist.<sup>17,25,27,28</sup>

The National Diabetes Services Scheme's *Diabetes and Emotional Health: A Practical Guide for Health Professionals Supporting Adults with Type 1 or Type 2 Diabetes*, 2nd edition, is a useful resource.<sup>17</sup>

### Conclusion

The impact of depression on diabetes is multifaceted and depends on the person's age and timing related to the diabetes journey, previous coping styles and how they are currently managing their diabetes, as well as their life situation and general health. It is important to acknowledge the prevalence of depression and diabetes co-occurring and ask about it. People presenting with both depression and diabetes are more likely to have complications from both conditions, have more challenges with managing these and require more support and understanding to overcome these difficulties. Narrowing down by asking about specific issues can enable targeted strategies.

Improving depression can improve diabetes control, and improving diabetes control can improve mental wellbeing; GPs can play an important role in managing this complexity. **ET**

### References

A list of references is included in the online version of this article ([www.endocrinologytoday.com.au](http://www.endocrinologytoday.com.au)).

COMPETING INTERESTS: None.



Up to 31,000 Ethiopian women still live with an untreated obstetric fistula injury - and around 1,000 new cases occur each year.

**Our goal is to make these numbers zero.**

Project Zero is Hamlin Fistula Ethiopia's most ambitious program in decades. It will accelerate the eradication of obstetric fistula, woreda by woreda (district by district).

**Be a part of this visionary program. Learn more or donate.** Scan the QR code above or call us on **02 9440 7001**.

# The impact of depression on diabetes

## An inextricable relationship

**KAY WILHELM** AM, MB BS, MD, FRANZCP  
**WEI-MAY SU** BSc(Med), MB BS, MMH(GP), FRACGP

### References

- Holt RI, de Groot M, Golden SH. Diabetes and depression. *Curr Diab Rep* 2014; 14: 491.
- Moulton CD, Pickup JC, Ismail K. The link between depression and diabetes: the search for shared mechanisms. *Lancet Diabetes Endocrinol* 2015; 3: 461-471.
- Diabetes Australia. 2023 snapshot: Diabetes in Australia. © Diabetes Australia. Available online at: <https://www.diabetesaustralia.com.au/wp-content/uploads/2023-Snapshot-Diabetes-in-Australia.pdf> (accessed July 2024).
- Katon W, Fan MY, Unützer J, Taylor J, Pincus H, Schoenbaum M. Depression and diabetes: a potentially lethal combination. *J Gen Intern Med* 2008; 23: 1571-1575.
- Tomic D, Shaw JE, Magliano DJ. The burden and risks of emerging complications of diabetes mellitus. *Nat Rev Endocrinol* 2022; 18: 525-539.
- Doolin K, Farrell C, Tozzi L, Harkin A, Frodl T, O'Keane V. Diurnal hypothalamic-pituitary-adrenal axis measures and inflammatory marker correlates in major depressive disorder. *Int J Mol Sci* 2017; 18: 2226.
- Bhandage AK, Jin Z, Korol SV, et al. GABA regulates release of inflammatory cytokines from peripheral blood mononuclear cells and CD4+ T cells and is immunosuppressive in type 1 diabetes. *EBioMedicine* 2018; 30: 283-294.
- de Cossio LF, Fourrier C, Sauvant J, et al. Impact of prebiotics on metabolic and behavioral alterations in a mouse model of metabolic syndrome. *Brain Behav Immun* 2017; 64: 33-49.
- de Vet E, de Ridder DT, de Wit JB. Environmental correlates of physical activity and dietary behaviours among young people: a systematic review of reviews. *Obes Rev* 2011; 12: 130-142.
- Amuda AT, Berkowitz SA. Diabetes and the built environment: evidence and policies. *Curr Diab Rep* 2019; 19: 35.
- Gonzalez JS, Peyrot M, McCarl LA, et al. Depression and diabetes treatment nonadherence: a meta-analysis. *Diabetes Care* 2008; 31: 2398-2403.
- van der Feltz-Cornelis C, Allen SF, Holt RIG, Roberts R, Nouwen A, Sartorius N. Treatment for comorbid depressive disorder or subthreshold depression in diabetes mellitus: systematic review and meta-analysis. *Brain Behav* 2021; 11: e01981.
- Petrak F, Baumeister H, Skinner TC, Brown A, Holt RIG. Depression and diabetes: treatment and health-care delivery. *Lancet Diabetes Endocrinol* 2015; 3: 472-485.
- Diabetes Prevention Program Research Group. Depressive symptoms, antidepressant medication use, and inflammatory markers in the Diabetes Prevention Program. *Psychosom Med* 2018; 80: 167-173.
- Wilhelm K, Reddy J, Crawford J, Robins L, Campbell L, Proudfoot J. Thimportance of screening for mild depression in adults with diabetes. *Transl Biomed* 2017; 8:1 doi:10.2167/2172-0479.1000101.
- Reddy J, Wilhelm K, Campbell L. Putting PAID to diabetes-related distress: the potential utility of the Problem Areas in Diabetes (PAID) scale in patients with diabetes. *Psychosomatics* 2013; 54: 44-51.
- Hendrieckx C, Halliday JA, Beeney LJ, Speight J. Diabetes and emotional health: a practical guide for health professionals supporting adults with type 1 or type 2 diabetes. 2nd ed. Canberra: National Diabetes Services Scheme; 2020. Available online at: <https://www.ndss.com.au/wp-content/uploads/resources/diabetes-emotional-health-handbook.pdf> (accessed July 2024).
- Aroda VR, Knowler WC, Crandall JP, et al. Diabetes Prevention Program Research Group. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. *Diabetologia* 2017; 60: 1601-1611.
- Calcutt NA. Diabetic neuropathy and neuropathic pain: a (con)fusion of pathogenic mechanisms? *Pain* 2020; 161 Suppl 1: S65-S86.
- Nouwen A, Winkley K, Twisk J, et al. Type 2 diabetes mellitus as a risk factor for the onset of depression: a systematic review and meta-analysis. *Diabetologia* 2010; 53: 2480-2486.
- Fisher L, Gonzalez JS, Polonsky WH. The confusing tale of depression and distress in patients with diabetes: a call for greater clarity and precision. *Diabet Med* 2014; 31: 764-772.
- Ciechanowski P, Russo J, Katon W, et al. Influence of patient attachment style on self-care and outcomes in diabetes. *Psychosom Med* 2004; 66: 720-728.
- Wilhelm K, Tietze T. Difficult doctor-patient interactions: applying principles of attachment-based care. *Med Today* 2016; 17(1-2): 36-44.
- Newby J, Robins L, Wilhelm K, et al. Web-based cognitive behaviour therapy for depression in people with diabetes mellitus: a randomised controlled trial. *J Med Internet Res* 2017; 19: e157.
- Wilhelm K, May R. Interpersonal therapy in the general practice setting. *Med Today* 2017; 18(8): 41-49.
- Amsberg S, Wijk I, Livheim F, Toft E, Johansson U-B, Anderbro T. Acceptance and commitment therapy (ACT) for adult type 1 diabetes management: study protocol for a randomised controlled trial. *BMJ Open* 2018; 8: e022234.
- Royal College of General Practitioners (RACGP). Management of type 2 diabetes: a handbook for general practice. Melbourne: RACGP and Diabetes Australia; 2020.
- Boyce P, Ma C. Choosing an antidepressant. *Aust Prescr* 2021; 44: 12-15.